Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). (EUCLID)
Epstein-Barr Virus Infections, Lymphoproliferative Disorders
About this trial
This is an interventional treatment trial for Epstein-Barr Virus Infections
Eligibility Criteria
Inclusion Criteria: Patients falling into one of the following categories: Organ transplant recipients at high risk of developing LPD: EBV seronegative recipients Organ transplant recipients receiving OKT3 for immunosuppression Organ transplant recipients with evidence of LPD Organ transplant recipients with EBV DNA level >1,000 copies Age <70 yrs old Signed informed consent obtained from patient/guardian CTLs available Performance status; ECOG £ 2 Creatinine < 3X normal Bilirubin < 5X normal AST < 5X normal Has not received any other investigational cellular therapies within the past 30 days. Exclusion criteria: Patients with a severe intercurrent infection Patients with life expectancy of less than 6 weeks Patients receiving supplemental oxygen.
Sites / Locations
- Texas Children's Hospital
- The Methodist Hospital
Arms of the Study
Arm 1
Experimental
Treatment
Each patient will receive a Biological/Vaccine Intravenous injection of EBV specific CTLs